November 3, 2017

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC). The study, led by first authors Karinna Almodovar, Ph.D., and Wade Iams, M.D., and principal investigator Christine Lovly, M.D., Ph.D., assistant professor of Medicine, was published online Sept. 23 in the Journal of Thoracic Oncology.